DSP Clinical Research ranked #1674 on Inc. 5000 list

DSP Clinical Research achieved a ranking of No. 1674 on the prestigious Inc. 5000 list. DSP provides customized contract research services for small to mid-size pharmaceutical and biotechnology companies conducting Phase I to IV clinical studies.

“The leaders of the companies on this year's Inc. 5000 have figured out how to grow their businesses during the longest recession since the Great Depression”

The Inc. 5000 is an exclusive ranking of the nation's fastest-growing private companies. The list represents the most comprehensive look at the most important segment of the economy—America's independent-minded entrepreneurs.

DSP President Darlene Panzitta said, "It's an honor to earn this recognition for the third consecutive time. DSP continues our steady growth because we bring a proven, unique approach to every customer's clinical research study. We've earned a reputation for delivering quality data while providing hands-on customer service."

DSP implements proven procedures, reporting systems and technologies to ensure that it consistently meets client deadlines on time and within budget. DSP's flexible service modules enable clients to contract for precisely the type and amount of support they need. This approach enables DSP to complement clients' own clinical experience, resources, and staff.

"The leaders of the companies on this year's Inc. 5000 have figured out how to grow their businesses during the longest recession since the Great Depression," said Inc. president Bob LaPointe. "The 2010 Inc. 5000 showcases a particularly hardy group of entrepreneurs."